Tag Archives: Federal Circuit

Allvoice Decision Provides Roadmap For Software-based Inventions

Posted on May 29, 2015 by Warren Woessner

Guest post from Greg Stark, attorney at Schwegman Lundberg & Woessner. In a refreshing break from Alice/Mayo abstract idea based 35 U.S.C. § 101 rejections, the Federal Circuit released a decision invalidating certain claims of U.S. Patent No. 5,799,273 as … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | Leave a comment

Apotex Petitions Supreme Court to Review Therasense Standards

Posted on May 21, 2015 by Warren Woessner

In Apotex, Inc. v. UCB, Inc., Appeal No. 2013-1674 (Fed. Cir. August 15, 2014) the court affirmed the district court’s ruling that one actor, Dr. Sherman, the chairman of Apotex had committed inequitable conduct by engaging in what the court … Continue reading →

Posted in Inequitable Conduct/Rule 56 | Tagged , , , , , , , | Leave a comment

Enzo Biochem V. Applera Corp. – When “Words Can Hurt You”

Posted on March 19, 2015 by Warren Woessner

On March 16, 2015 (Appeal no. 2014-1321), the Fed. Cir. reversed the district court’s construction of a claim term relating to the scope of “A,” a moiety capable of direct or indirect signaling that is attached by a linker to … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , | Leave a comment

Novartis Wins Landmark Biosimilar Approval

Posted on March 9, 2015 by Warren Woessner

Novartis Navigates The FDA-ACA Maze – Gets Approval For Generic Neuprogen. Amgen will soon find itself in a price war with Sandoz – a Novartis company – as it tries to maintain its share of the market for Neuprogen (filgraslim). … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment